U.S. Department of Health & Human Services

NLM Digital Collections

Search

Search Constraints

Start Over You searched for: Subjects Humans Remove constraint Subjects: Humans Genre Technical Report Remove constraint Genre: Technical Report Dates by Range 2000 and later Remove constraint Dates by Range: 2000 and later
Number of results to display per page

Search Results

302. Health care improvement in Pueblo, Colorado: building on common ground

nlm:nlmuid-101712867-pdf

303. Emergency use authorization of medical products and related authorities: guidance for industry and other stakeholders

nlm:nlmuid-101712946-pdf

304. Form FDA 3674--certifications to accompany drug, biological product, and device applications/submissions: guidance for sponsors, industry, researchers, investigators, and food and drug administration staff

nlm:nlmuid-101712948-pdf

305. E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs--questions and answers (R3)

nlm:nlmuid-101712951-pdf

307. IRB waiver or alteration of informed consent for clinical investigations involving no more than minimal risk to human subjects: guidance for sponsors, investigators, and institutional review boards

nlm:nlmuid-101713098-pdf

309. Federal subsidies for health insurance coverage for people under age 65: 2017 to 2027

nlm:nlmuid-101713191-pdf

311. Generic Drug User Fee Amendments of 2012: questions and answers related to self-identification of facilities, review of generic drug submissions, and inspections and compliance

nlm:nlmuid-101713196-pdf

312. Antibacterial therapies for patients with an unmet medical need for the treatment of serious bacterial diseases

nlm:nlmuid-101713206-pdf

314. Use of real-world evidence to support regulatory decision-making for medical devices: guidance for industry and Food and Drug Administration staff

nlm:nlmuid-101713224-pdf

316. Design considerations and pre-market submission recommendations for interoperable medical devices: guidance for industry and Food and Drug Administration staff

nlm:nlmuid-101713256-pdf

317. Evaluation and reporting of age-, race-, and ethnicity-specific data in medical device clinical studies: guidance for Industry and Food and Drug Administration staff

nlm:nlmuid-101713258-pdf

318. Establishing the performance characteristics of in vitro diagnostic devices for the detection or detection and differentiation of human papillomaviruses: guidance for Industry and Food and Drug Administration staff

nlm:nlmuid-101713268-pdf

319. Q4B evaluation and recommendation of pharmacopoeial texts for use in the ICH regions: annex 1(R1) : residue on ignition/sulphated ash general chapter

nlm:nlmuid-101713272-pdf

320. Q4B evaluation and recommendation of pharmacopoeial texts for use in the ICH regions: annex 2(R1) : test for extractable volume of parenteral preparations general chapter

nlm:nlmuid-101713277-pdf

321. Q4B evaluation and recommendation of pharmacopoeial texts for use in the ICH regions: annex 3(R1) : test for particulate contamination : subvisible particles general chapter

nlm:nlmuid-101713281-pdf

322. Q4B evaluation and recommendation of pharmacopoeial texts for use in the ICH regions: annex 4A(R1) : microbiological examination of nonsterile products : microbial enumeration tests general chapter

nlm:nlmuid-101713288-pdf

323. Q4B evaluation and recommendation of pharmacopoeial texts for use in the ICH regions: annex 4B(R1) : microbiological examination of nonsterile products : tests for specified microorganisms general chapter

nlm:nlmuid-101713291-pdf

324. Q4B evaluation and recommendation of pharmacopoeial texts for use in the ICH regions: annex 4C(R1) : microbiological examination of nonsterile products : acceptance criteria for pharmaceutical preparations and substances for pharmaceutical use general chapter

nlm:nlmuid-101713296-pdf

325. Q4B evaluation and recommendation of pharmacopoeial texts for use in the ICH regions: annex 5(R1) : disintegration test general chapter

nlm:nlmuid-101713299-pdf

326. Q4B evaluation and recommendation of pharmacopoeial texts for use in the ICH regions: annex 9(R1) : tablet friability general chapter

nlm:nlmuid-101713302-pdf

327. Q4B evaluation and recommendation of pharmacopoeial texts for use in the ICH regions: annex 10(R1) : polyacrylamide gel electrophoresis general chapter

nlm:nlmuid-101713306-pdf

328. Antibiotics: FDA has encouraged development, but needs to clarify the role of draft guidance and develop qualified infectious disease product guidance : report to Congressional requesters

nlm:nlmuid-101713330-pdf

329. Workplace safety and health: information on OSHA training for workers on workplace hazards : report to the Chairman, Subcommittee on Health, Employment, Labor, and Pensions, Committee on Education and the Workforce, House of Representatives

nlm:nlmuid-101713337-pdf

331. Antibiotic resistance: more information needed to oversee use of medically important drugs in food animals : report to Congressional requesters

nlm:nlmuid-101713360-pdf

333. Medicare provider education: oversight of efforts to reduce improper billing needs improvement : report to the Chairman, Committee on Finance, U.S. Senate

nlm:nlmuid-101713369-pdf

334. Medicaid program integrity: CMS should build on current oversight efforts by further enhancing collaboration with states : report to the Chairman, Committee on Finance, U.S. Senate

nlm:nlmuid-101713370-pdf

335. Pediatric trauma centers: availability, outcomes, and federal support related to pediatric trauma care : report to Congressional requesters

nlm:nlmuid-101713371-pdf

336. Veterans' health care: preliminary observations on veterans' access to choice program care : testimony before the Committee on Veterans' Affairs, House of Representatives

nlm:nlmuid-101713373-pdf

338. Veterans health administration: actions needed to better recruit and retain clinical and administrative staff : testimony before the Subcommittee on Health, Committee on Veterans' Affairs, House of Representatives

nlm:nlmuid-101713377-pdf

343. Medicaid personal care services: more harmonized program requirements and better data are needed : testimony before the Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, House of Representatives

nlm:nlmuid-101713411-pdf

344. Emerging infectious diseases: actions needed to ensure improved response to Zika virus disease outbreaks : testimony before the Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, House of Representatives

nlm:nlmuid-101713412-pdf

345. Veterans Affairs: improper payment estimates and ongoing efforts for reduction : testimony before the Subcommittee on Oversight and Investigations, Committee on Veterans' Affairs, House of Representatives

nlm:nlmuid-101713413-pdf

346. Q4B evaluation and recommendation of pharmacopoeial texts for use in the ICH regions: annex 8 (R1) : sterility test general chapter

nlm:nlmuid-101713430-pdf

347. Preliminary analysis of legislation that would replace subsidies for health care with block grants

nlm:nlmuid-101713545-pdf

348. Adding employer contributions to health insurance to Social Security's earnings and tax base

nlm:nlmuid-101646652-pdf

350. When the nest egg cracks: financial consequences of health problems, marital status changes, and job layoffs at older ages

nlm:nlmuid-101468696-pdf

353. Health insurance and the labor supply decision of older workers: evidence from the U.S. Department of Veterans Affairs

nlm:nlmuid-101468710-pdf

356. Health insurance coverage and the disability insurance application decision

nlm:nlmuid-101468769-pdf

359. Medicare, retirement costs, and labor supply at older ages

nlm:nlmuid-101468776-pdf

365. The well-being of retirees: evidence using subjective data

nlm:nlmuid-101468791-pdf

367. What happens to health benefits after retirement?

nlm:nlmuid-101469237-pdf

369. Will health care costs erode retirement security?

nlm:nlmuid-101469311-pdf

370. Is private long-term care insurance the answer?

nlm:nlmuid-101469321-pdf

372. Medicaid and long-term care: how will rising costs affect services for an aging population?

nlm:nlmuid-101469329-pdf

386. Reimagining federal and state roles for health reform under the Patient Protection and Affordable Care Act

nlm:nlmuid-101553101-pdf

390. Integration, concentration, and competition in the provider marketplace

nlm:nlmuid-101589988-pdf

393. Supply side implications of insurance coverage expansions

nlm:nlmuid-101590014-pdf

395. Payment and delivery reform: can implementation keep up with policy?

nlm:nlmuid-101608874-pdf

397. The future of health care for military personnel and veterans

nlm:nlmuid-101636954-pdf

400. Public health's role in a post-ACA world

nlm:nlmuid-101648397-pdf